Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial have shown that Pfizer’s SPIRIVA HandiHaler (tiotropium bromide inhalation powder) sustains i… more →
GPCR Newscrimsoncanary wrote 1 year ago: Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial … more →
crimsoncanary wrote 1 year ago: Data published in teh Annals of Internal Medicine show that ipratropium may elevate risk for all-cau … more →
crimsoncanary wrote 1 year ago: GSK have published a series of biphenyl piperazine muscarinic acetylcholine receptor antagonists … more →
crimsoncanary wrote 1 year ago: Almirall has received a 15 million dollar payment from Forest Laboratories in connection with its ph … more →
crimsoncanary wrote 1 year ago: GSK have initiated a Phase I trial of Muscarinic M1 antagonist GSK1034702 … more →
crimsoncanary wrote 1 year ago: Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160 … more →
crimsoncanary wrote 1 year ago: Theravance/GSK have announced positive results from a Phase II study of GSK961081 for the treatment … more →
crimsoncanary wrote 1 year ago: Mithridion has commenced a Phase I clinical trial of its investigational drug MCD-386 in Alzheimers. … more →
crimsoncanary wrote 1 year ago: Sciele Pharma have completed a phase III trial for Glycopyrrolate Liquid for the treatment of chroni … more →
crimsoncanary wrote 1 year ago: Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long ac … more →
crimsoncanary wrote 1 year ago: Acadia’s ACP-104 did not meet its primary endpoint of antipsychotic efficacy in a Phase IIb Sc … more →
crimsoncanary wrote 1 year ago: Researchers from the University of Florence, University Camerino and the Inst Sup di Sanita have pub … more →
crimsoncanary wrote 1 year ago: Watson’s Oxybutynin topical gel has demonstrated improved skin tolerability compared to the ox … more →